Assessing the impact of efalizumab on nail, scalp and palmoplantar psoriasis and on quality of life: Results from a multicentre, open-label, phase IIIb/IV trial

Archives of Drug Information

Volumn 2, Issue 4, 2009, Pages 66-70

  Katsambas, Andreas ^a   Peris, Ketty ^b   Vena, Gino ^c   Freidmann, Peter ^d   Wozel, Gottfried ^e   Daudén, Esteban ^f   Licu, Daiana ^g   Placchi, Mauro ^g   De La Brassinne, Michel ^h  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g MERCK SERONO S A   (Switzerland)

^h UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Efalizumab; Nail psoriasis; Palmoplantar psoriasis; Quality of life; Scalp psoriasis

Indexed keywords

EFALIZUMAB;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DERMATOLOGY LIFE QUALITY INDEX; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL PSORIASIS; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; RATING SCALE; SCALP PSORIASIS; SCORING SYSTEM; SHORT FORM 36; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77953427758     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2009.00023.x     Document Type: Article

References (15)

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005, 64(2):8-23. suppl
2. Larko O. Problem sites: Scalp, palm and sole, and nail. Dermatol Clin 1995, 13:771-7.
3. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007, 20:60-7.
4. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice. J Am Acad Dermatol 2003, 49:271-5.
5. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006, 33:1452-6.
6. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001, 2:159-65.
7. Wozel G. Psoriasis treatment in difficult locations: Scalp, nails, and intertriginous areas. Clin Dermatol 2008, 26:448-59.
8. Lotti T, Chimenti S, Katsambas A, Ortonne J-P, Dubertret L, Licu D. Efficacy and safety of efalizumab in patients with moderate-to-severe plaque psoriasis resistant to previous anti-psoriatic treatment: Results of a multicentre, open-label, Phase IIIb/IV trial. Arch Drug Info 2009
9. Takahashi MD, Chouela EN, Dorantes GL, Roselino AM, Santamaria J, Allevato MA. Efalizumab in the treatment of scalp, palmoplantar, and nail psoriasis: Results of a 24-week Latin American study. Arch Drug Info 2009
10. Leonardi C, Sofen H, Krell J, Caro I, Compton P, Sobell JM. Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot plaque psoriasis. J Am Acad Dermatol 2007, 56:AB48.
11. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003, 290:3073-80.
12. Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995, 133:575-8.
13. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005, 141:31-8.
14. Ortonne JP, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: Results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005, 5:13.
15. Wahl AK, Mørk C, Lillehol BM, Myrdal AM, Helland S, Hanestad BR. Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology. Acta Derm Venereol 2006, 86:198-201.